QL2107
Phase 3Small molecule
Qilu Pharmaceutical Co., Ltd.QL2107 is one of 242 small molecule programs targeting Extensive-stage Small-cell Lung Cancer. It is currently in Phase 3.
7
Indications
8
Total Trials
7
Active Trials
241
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Alunbrig
TakedaPhase 3
Zykadia
NovartisPhase 3
Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
QL2107
Qilu Pharmaceutical Co., Ltd.Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumor1 trial
Patients With Advanced Solid Tumors1 trial
Adult1 trial
Biliary Tract Cancer1 trial
Adenocarcinoma1 trial
3 more indications
Efficacy1 trial
Non-Small Cell Lung Cancer1 trial
Extensive-stage Small-cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QL2107. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details